By Mike Yamamoto, managing editor of OptionMonsterNEW YORK -- Traders are looking for Edwards Lifesciences (EW) to rebound after its synthetic heart valve won regulatory approval for broader use last week.
Bulls Look for Rebound at Edwards Lifesciences
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts